Patents by Inventor Matthew M. Hamilton

Matthew M. Hamilton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240360121
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: March 6, 2024
    Publication date: October 31, 2024
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • Patent number: 11958849
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: April 16, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • Publication number: 20230124815
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: April 25, 2022
    Publication date: April 20, 2023
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • Patent number: 11370786
    Abstract: Disclosed herein are compounds of structural Formula VIIa or VIIb: or a pharmaceutically acceptable salt thereof, and compositions thereof useful in the treatment of GLS1 mediated diseases, such as cancer. Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: June 28, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • Publication number: 20220153729
    Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: June 29, 2021
    Publication date: May 19, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. HADIDA RUAH, Matthew M. HAMILTON, Mark MILLER, Peter D.J. GROOTENHUIS
  • Patent number: 11084804
    Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: August 10, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. Hadida Ruah, Matthew M. Hamilton, Mark Miller, Peter D. J. Grootenhuis
  • Publication number: 20210024505
    Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: February 13, 2020
    Publication date: January 28, 2021
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. HADIDA RUAH, Matthew M. HAMILTON, Mark MILLER, Peter D.J. GROOTENHUIS
  • Publication number: 20200407353
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 10, 2020
    Publication date: December 31, 2020
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • Patent number: 10766892
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: September 8, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • Patent number: 10626111
    Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTC”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: April 21, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. Hadida Ruah, Matthew M. Hamilton, Mark Miller, Peter D. J. Grootenhuis
  • Publication number: 20190322650
    Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: November 21, 2018
    Publication date: October 24, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. HADIDA RUAH, Matthew M. HAMILTON, Mark MILLER, Peter D.J. GROOTENHUIS
  • Publication number: 20190270736
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 5, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • Patent number: 10344025
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: July 9, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • Publication number: 20180282311
    Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: June 1, 2016
    Publication date: October 4, 2018
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. HADIDA RUAH, Matthew M. Hamilton, Mark Miller, Peter D.J. Grootenhuis, Brian Bear, Jason McCartney, Jinglan Zhou
  • Patent number: 9809588
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: November 7, 2017
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • Publication number: 20170291895
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 12, 2017
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • Publication number: 20170107205
    Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: June 1, 2016
    Publication date: April 20, 2017
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. HADIDA RUAH, Matthew M. Hamilton, Mark Miller, Peter D.J. Grootenhuis, Brian Bear, Jason McCartney, Jinglan Zhou
  • Publication number: 20160009704
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 2, 2015
    Publication date: January 14, 2016
    Applicant: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • Publication number: 20160002204
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 3, 2015
    Publication date: January 7, 2016
    Applicant: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Christopher Lawrence Carroll, Timothy McAfoos, Wylie Palmer, Zachary Herrera